Neldaleucel
Alternative Names: MT-601Latest Information Update: 23 Aug 2024
At a glance
- Originator Marker Therapeutics Inc
- Developer Marker Cell Therapy; Marker Therapeutics Inc
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Pancreatic cancer
- Phase I Non-Hodgkin's lymphoma
- Preclinical Haematological malignancies
Most Recent Events
- 23 Aug 2024 Marker Therapeutics plans a phase I PANCEA trial for Pancreatic cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in USA (IV) (NCT06549751)
- 15 May 2024 Updated efficacy data from the phase I APOLLO trial in Non-Hodgkin's lymphoma released by Marker Therapeutics
- 23 Apr 2024 Updated efficacy data from the phase I/II TACTOPS trial in Pancreatic cancer released by Marker Therapeutics, prior to April 2024